Thoracic Cancer Research

Thoracic Cancer Research

Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.

Clinical Trials

Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
A Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody for the Treatment of Patients with Advanced Solid Tumors
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrent Disease in Cutaneous Squamous Cell Carcinoma
An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled In a Genentech and/or Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Disease Team Members

Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.
Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
A Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody for the Treatment of Patients with Advanced Solid Tumors
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrent Disease in Cutaneous Squamous Cell Carcinoma
An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled In a Genentech and/or Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)